Journal of Clinical Oncology 2020

56 papers
The 2020 edition of the Journal of Clinical Oncology featured 55 papers that emphasized patient-centered care, palliative interventions, and therapeutic advancements. A significant portion of the research focused on supportive care, including studies on patient-reported outcomes in older adults with gastrointestinal cancer and the relationship between caregiver burden and psychological distress in stem cell transplant recipients. Prolific authors such as Jennifer S. Temel and Areej El-Jawahri contributed to this focus on symptom monitoring and palliative radiotherapy consultation. Clinical research from this year also explored novel treatment strategies and diagnostic technologies. Notable work included phase III survival results for nasopharyngeal carcinoma treatments and phase I/II trials investigating oncolytic viruses combined with immune checkpoint inhibition for colorectal cancer. Additionally, the journal featured research on gender disparities in lung cancer and the application of image-based consensus molecular subtype classification. These contributions reflect a trend toward integrating psychological health, health equity, and advanced imaging into clinical practice.

Top Research Directions

The 5 research directions with Journal of Clinical Oncology 2020 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.

#DirectionPapersShare
1Causal Attribution Challenges in Single Arm Trials11.8%
2Remodeling the Tumor Microenvironment with Combination Immunotherapy11.8%
3Reprogramming the Microenvironment to Overcome Immunotherapy Resistance11.8%
4Standardized Frameworks for Tumor Response Assessment11.8%
5Standardized Grading of Clinical Toxicities and Complications11.8%

Download all directions as CSV

About this data

Papers. Journal of Clinical Oncology 2020 lists 56 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.

Data. Counts come from Lacuna’s data build of 2026-11-20 and change as papers are added. Tables as CSV: directions. Cite as: Lacuna, “Journal of Clinical Oncology 2020”, https://lacuna.tiptreesystems.com/venue/journal-of-clinical-oncology/2020.

Top Authors

AuthorPapers
Bradford J Wood4
Jorge J. Nieva4
Aly A Khan2
Christopher Kanan2
Anobel Odisho1
Benjamin Haibe-Kains1
Bernhard Zimmermann1
Chad Vanderbilt1
Chitta Baral1
Derrick Renner1
Desamparados Roda1
Himanshu Sethi1
Jakob Nikolas Kather1
Jimeng Sun1
Juan Antonio Carbonell‐Asins1
Junyi Gao1
Madeline R Abbott1
Marisol Huerta1
Noelia Tarazona1
Qi Long1

Papers

Title
Acquired resistance to PD-1 blockade in NSCLC.
Anlotinib (AL3818) plus pemetrexed in patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A single-arm, open-label, phase II study.
A phase I/II study of Pexa-Vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer.
A phase I study of SHR6390, a cyclin-dependent kinase 4/6 inhibitor in patients with advanced breast cancer (ABC).
A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.
Artificial intelligence assisted bone lesion detection and classification in computed tomography scans of prostate cancer patients.
Association of PI-RADS categories and PSA density with active surveillance progression in patients with prostate cancer.
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC).
Characterization of NRG1 gene fusion events in solid tumors.
Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC.
Computational pathological identification of prostate cancer following neoadjuvant treatment.
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
Disparities in receipt of molecular imaging in biochemical recurrent prostate cancer.
Do differences in the microbiome explain early onset in colon cancer?
Does size matter? Lesion size as an indicator of number of cores needed to detect clinically significant prostate cancer.
Effect of local therapies on survival in patients with metastatic adrenocortical carcinoma.
Efficacy of immune checkpoint blockade alone or combined with chemotherapy and smoking status in NSCLC: A systematic review and meta-analysis.
Enhanced co-expression extrapolation (COXEN) gene selection method for building anticancer drug response prediction models.
Epigenetic imprinted gene biomarkers significantly improve the accuracy of presurgical bronchoscopy diagnosis of lung cancer.
GEM20110714: Final overall survival results of the phase III study of first-line gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma.
Gender disparities in hormone positive lung cancer.
Genomic landscape and clinicopathological characteristics of lung cancer in young Chinese patients.
Genomic profiling identified novel prognostic biomarker in Chinsese glioma patients.
H&E image-based consensus molecular subtype classification of colorectal cancer using weak labeling.
Independent validation of paige prostate: Assessing clinical benefit of an artificial intelligence tool within a digital diagnostic pathology laboratory workflow.
Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study.
Is there a genomic fingerprint of Radon (Rn)-induced lung cancer (LC)? Comparison of genomic alterations in LC specimens from high and low Rn zones.
Learning relevant H&E slide morphologies for prediction of colorectal cancer tumor mutation burden using weakly supervised deep learning.
Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer.
Long-term survival of combined ablation therapy and tremelimumab with or without durvalumab in advanced hepatocellular carcinoma.
Novel evidence synthesis system to support living systematic reviews and living guidelines for cancer immunotherapy.
Pathologic outcomes of MRI invisible tumors in prostate cancer.
Patient characteristics associated with time-to-consult for inpatient palliative radiotherapy.
Patient-reported outcomes (PROs) in older adults with gastrointestinal (GI) cancer undergoing surgery.
Patient trial matching using pseudo-siamese network.
PD-L1 positive esophagogastric (EG) cancer is associated with distinct bacteria.
Phase II study of nivolumab (anti-PD1), tadalafil, and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic ca
Phase II trial of guadecitabine priming and pembrolizumab in platinum resistant recurrent ovarian cancer.
Prediction of histologic and molecular subsets of soft tissue sarcoma using deep learning.
Prediction of mental health disorder onset and impact on emergency visits following a cancer diagnosis.
Radiomic response evaluation of recurrent or metastatic head and neck squamous cell cancer (R/M HNSCC) patients receiving pembrolizumab on KEYNOTE-012 study.
Randomized trial of a symptom monitoring intervention for hospitalized patients with advanced cancer (NCT03396510).
REACT: A feasibility study to test the integration of a cancer registry early case ascertainment process via electronic pathology reporting with an online clinical trial matching tool.
Relationship between caregiver burden and psychological distress among stem cell transplant (SCT) recipients prior to transplant.
Relationships among skeletal muscle, symptom burden, health care use, and survival in hospitalized patients with advanced cancer.
Renal biopsy cell cycle proliferation (CCP) score to predict adverse surgical pathology in renal cell carcinoma.
Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC).
Safety, tolerability, and preliminary pharmacokinetic/pharmacodynamic profile of JMT103 in patients with bone metastases from solid tumors: A multicenter, open-label, dose-escalation, phase I clinical
Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlle

Page 1/2 next »